Aligos Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q3 2019 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Aligos Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q3 2019 to Q2 2024.
  • Aligos Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was $5.06M.
  • Aligos Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2024 was -$75.7M, a 7.92% increase year-over-year.
  • Aligos Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$87.7M, a 8.71% increase from 2022.
  • Aligos Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$96M, a 25.2% increase from 2021.
  • Aligos Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$128M, a 18.2% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$75.7M $5.06M +$23.9M Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-06
Q1 2024 -$99.6M -$34.9M -$11.9M -51.9% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-07
Q4 2023 -$87.7M -$27.9M -$6.01M -27.4% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-12
Q3 2023 -$81.7M -$18M +$580K +3.12% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-02
Q2 2023 -$82.3M -$18.8M +$1.13M +5.69% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-06
Q1 2023 -$83.4M -$23M +$12.7M +35.5% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-07
Q4 2022 -$96M -$21.9M +$15.8M +42% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-12
Q3 2022 -$112M -$18.6M +$14.5M +43.8% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-02
Q2 2022 -$126M -$19.9M +$9.89M +33.2% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-03
Q1 2022 -$136M -$35.6M -$7.94M -28.7% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q4 2021 -$128M -$37.7M -$3.3M -9.58% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-09
Q3 2021 -$125M -$33.1M +$173K +0.52% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-02
Q2 2021 -$125M -$29.8M -$9.02M -43.4% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 -$116M -$27.7M -$7.65M -38.2% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-04
Q4 2020 -$109M -$34.4M Oct 1, 2020 Dec 31, 2020 10-K 2022-03-10
Q3 2020 -$33.3M -$19.2M -137% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 -$20.8M Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-05
Q1 2020 -$20M Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-10
Q3 2019 -$14.1M Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-25
* An asterisk sign (*) next to the value indicates that the value is likely invalid.